长春瑞滨联合顺铂与吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效比较。

Comparison of vinorelbine-Cisplatin with gemcitabine-Cisplatin in patients with advanced non-small cell lung cancer.

作者信息

Ozkaya Sevket, Findik Serhat, Uzun Oguz, Atici Atilla Guven, Erkan Levent

机构信息

Specialist.

出版信息

Clin Med Circ Respirat Pulm Med. 2008 Apr 18;2:27-34. doi: 10.4137/ccrpm.s578.

DOI:10.4137/ccrpm.s578

PMID:21157519

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2990234/

Abstract

PURPOSE

The objective of this trial was to compare cisplatin-plus-vinorelbine regimen with cisplatin-plus-gemcitabine regimen in patients with stage IIIB-IV non-small cell lung cancer (NSCLC).

PATIENTS AND METHODS

Chemonaive patients with stage IIIB-IV NSCLC received either vinoelbine 30 mg/m(2) (days 1 and 8) plus cisplatin 80 mg/m(2) (day 1) every 21 days (VC arm) or gemcitabine 1250 mg/m(2) (days 1 and 8) plus cisplatin 80 mg/m(2) (day 1) every 21 days (GC arm).

RESULTS

One hundred thirtyfour patients (67 VC and 67 GC) were included to the study. Overall response rates for the VC arm (31.2%) were not significantly different from that of the GC arm (34.3%). There were no differences in overall survival and one-year survival rates. Median survival and one-year survival rates for the VC and GC groups were 10.6 and 11.5 months, 45% and 46.8%, respectively. Grade 3-4 thrombocytopenia was significantly higher on the GC arm (VC 1.4% v GC 8.9%, p < 0.05), as was febrile neutropenia on the VC arm (VC 8.9% v GC 1.4%, p < 0.05).

CONCLUSION

VC and GC demonstrated similar efficacy but there were differences in toxicity profiles.

摘要

目的

本试验的目的是比较顺铂联合长春瑞滨方案与顺铂联合吉西他滨方案治疗ⅢB - Ⅳ期非小细胞肺癌（NSCLC）患者的疗效。

患者与方法

初治的ⅢB - Ⅳ期NSCLC患者，每21天接受一次长春瑞滨30mg/m²（第1天和第8天）加顺铂80mg/m²（第1天）治疗（VC组），或吉西他滨1250mg/m²（第1天和第8天）加顺铂80mg/m²（第1天）治疗（GC组）。

结果

134例患者（67例VC组和67例GC组）纳入研究。VC组的总缓解率（31.2%）与GC组（34.3%）无显著差异。总生存率和一年生存率无差异。VC组和GC组的中位生存期和一年生存率分别为10.6个月和11.5个月，45%和46.8%。GC组3 - 4级血小板减少症显著高于VC组（VC组1.4%对GC组8.9%，p<0.05），VC组发热性中性粒细胞减少症显著高于GC组（VC组8.9%对GC组1.4%，p<0.05）。